Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHalma Regulatory News (HLMA)

Share Price Information for Halma (HLMA)

Share Price is delayed by 15 minutes
Get Live Data
4,664.00    -214.00 (-4.39%)
Bid:
4,682.00
Ask:
4,686.00
Spread: 4.00 (0.085%)
Market Cap: £17.62b
HLMA Live PriceLast checked at - London Stock Exchange

Intraday Halma Share Chart

Trading Update

25 Sep 2025 07:00

RNS Number : 7124A
Halma PLC
25 September 2025
 

Halma plc

Trading Update

Halma, the global group of life-saving technology companies focused on growing a safer, cleaner, healthier future for everyone, every day, today releases its scheduled trading update ahead of its half year end on 30 September 2025.

 

Strong progress in the first half; full year revenue growth guidance increased

We have made strong progress in the first half of this financial year, against a backdrop of varied market conditions and a challenging economic and geopolitical environment. Our continued delivery of strong, compounding growth and returns reflects the benefits of our Sustainable Growth Model, including our participation in diverse markets whose growth is supported by long-term drivers, the exceptional talent in our companies, and the autonomy we give our companies and people to respond rapidly to changing market conditions.

 

Based on our progress in the year to date and our current expectations for the remainder of the year, we now expect to deliver low double digit percentage organic constant currency1 revenue growth in this financial year. This compares to our previous guidance of upper single digit percentage organic constant currency1 revenue growth, with the increase being primarily driven by stronger-than-expected growth in photonics within the Environmental & Analysis Sector.

 

This growth is supported by order intake which remains ahead of both revenue in the year to date and the comparable period last year.

 

There is no change to our Adjusted EBIT margin2 guidance, which we continue to expect to be modestly above the middle of our target range of 19-23% in this financial year.

 

Our strong underlying cash generation and robust financial position is supporting continued strategic investment in future organic growth, as well as providing capacity to fund acquisitions. In the first half of the year, we expect our cash conversion to reflect incremental growth investment in working capital as well as capital investments across the Group. We expect full year cash conversion to be more in line with our KPI of 90%.

 

The appreciation of Sterling is having a negative currency translation effect on the group's results; we expect this effect to continue in the second half of the year3.

 

Further M&A progress; healthy acquisition pipeline

We have completed two acquisitions in the year to date. On 25 August, we acquired Brownline, a provider of advanced gyroscopic locating systems used by Horizontal Directional Drilling (HDD) contractors in trenchless underground drilling, for €150m (approximately £129m)4 as a standalone company for our Environmental & Analysis Sector. On 3 April, we acquired Nu Perspectives, a cryogenic therapy device engineering company, as a bolt-on for our Healthcare Sector company, Keeler, for £1.5m4. We continue to have a healthy acquisition pipeline.

 

We actively manage our portfolio of global businesses to ensure that it delivers strong growth and returns and is aligned with our purpose of growing a safer, cleaner, healthier future for everyone, every day. As a result, we made one disposal in the period, of AAI, for approximately £10m, net of disposal costs. In addition, our Environmental & Analysis Sector company Nuvonic entered into a licence, manufacturing and distribution agreement with their long-standing partner Fluidsmile in a number of Asian markets. Further details of these transactions are given in note 5 to this update.

 

Half Year Results

The Group's results for the half year ending 30 September 2025 will be released on 20 November 2025.

 

For further information, please contact:

Halma plc

Marc Ronchetti, Group Chief Executive +44 (0)1494 721 111

Carole Cran, Chief Financial Officer

Melanie Horton, Co-Head of Investor Relations +44 (0) 7554 013 396

Charles King, Co-Head of Investor Relations +44 (0) 7776 685 948

MHP

Oliver Hughes / Rachel Farrington / Ollie Hoare +44 (0)7817 458 804 / halma@mhpgroup.com

Notes:

1. Organic constant currency measures exclude the effect of movements in foreign exchange rates on the translation of revenue and profit into Sterling, as well as acquisitions in the year following completion and disposals.

2. Adjusted EBIT is earnings before interest and tax, and before amortisation and impairment of acquired intangible assets, acquisition items, and profit or loss on disposal of businesses. Adjusted EBIT margin is defined as Adjusted EBIT expressed as a percentage of revenue. Our guidance excludes the one-off benefit from the Nuvonic transaction which was completed in the half year (see note 5 below).

3. Sterling has strengthened in the year relative to many currencies, including the US Dollar and Euro and the currency translation impact on the Group's results for the financial year ended 31 March 2026 is expected to be negative. Based on exchange rates of Sterling/US Dollar 1:1.35 and Sterling/Euro 1:1.16, we would expect approximately a £74m negative revenue effect and approximately a £17m negative profit effect in the 2026 financial year, compared to the 2025 financial year.

4. On a cash- and debt-free basis.

5. On 25 July 2025, the group completed the sale of AAI, a designer and manufacturer of smoke, heat, and carbon monoxide detectors and HVAC-mounted duct smoke and carbon monoxide detectors, principally for the US residential market, for a total cash consideration of US$14m (approximately £10m) on a cash- and debt-free basis, net of disposal costs. In the financial year ended 31 March 2025, AAI reported revenue of US$54m (approximately £42m). A loss, which is expected to be approximately £5m, will be recognised in statutory profit on disposal.

On 15 May 2025, Nuvonic, an Environmental & Analysis Sector company, granted Fluidsmile Fluid Tech Ltd (Fluidsmile), a longstanding partner of Nuvonic in China, an exclusive trademark licence and related manufacturing and distribution rights to sell certain Nuvonic products in China and other agreed southeastern Asian markets, for RMB95m (approximately £10m). Nuvonic also acquired a 35% associate investment in Fluidsmile for RMB95m (approximately £10m) on the same date. As a result of these transactions, a one-off gain of £8m will be recognised in Adjusted EBIT2 in the current financial year.

6. This Trading Update is based upon unaudited management accounts information. Forward-looking statements have been made by the Directors in good faith using information available up until the date that they approved this statement. Forward-looking statements should be regarded with caution because of the inherent uncertainties in economic trends and business risks.

7. A copy of this announcement, together with other information about Halma, may be viewed on our website www.halma.com.

About Halma

Halma is a global group of life-saving technology companies, focused on growing a safer, cleaner, healthier future for everyone, every day. Its purpose defines the three broad markets it operates in:

· Safety - Protecting the safety of people and assets as populations grow and the demand on infrastructure increases.

· Environment - Addressing the impacts of climate change, pollution and waste, protecting life-critical resources and supporting scientific research.

· Health - Meeting the increasing demand for better healthcare as chronic illness rises, driven by growing and ageing populations and lifestyle changes.

 

It employs over 9,000 people in more than 20 countries, with major operations in the UK, Mainland Europe, the USA and Asia Pacific. Halma is listed on the London Stock Exchange (LON: HLMA) and is a constituent of the FTSE 100 index.

 

Halma has been named as one of Britain's Most Admired Companies for the past six years.

 

For more information www.halma.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSEAFWLEISESU
Date   Source Headline
21st Nov 20177:00 amRNSHalf-year Report
1st Nov 20177:00 amRNSAcquisition
4th Oct 20175:54 pmRNSDirector/PDMR Shareholding
28th Sep 20179:57 amRNSDirector/PDMR Shareholding
27th Sep 20177:00 amRNSTrading Statement
11th Sep 201712:19 pmRNSDirector Declaration
7th Sep 20179:27 amRNSDirector Declaration
1st Sep 20175:08 pmRNSTotal Voting Rights
16th Aug 20174:02 pmRNSDirector/PDMR Shareholding
7th Aug 20177:00 amRNSAcquisition
1st Aug 201710:39 amRNSTotal Voting Rights
31st Jul 201712:00 pmRNSNotice of Board Change
20th Jul 20173:57 pmRNSResult of AGM
19th Jul 20172:21 pmRNSDirector Declaration
4th Jul 20173:39 pmRNSDirector/PDMR Shareholding
3rd Jul 201711:29 amRNSTotal Voting Rights
21st Jun 20175:22 pmRNSAnnual Financial Report
13th Jun 20177:00 amRNSFinal Results
1st Jun 20173:02 pmRNSTotal Voting Rights
30th May 201711:00 amRNSNotice of Results
2nd May 20173:39 pmRNSTotal Voting Rights
6th Apr 20179:00 amRNSNotice of Board change
3rd Apr 201711:12 amRNSTotal Voting Rights
23rd Mar 20177:00 amRNSTrading Update and Audit Tender
1st Mar 201712:41 pmRNSTotal Voting Rights
13th Feb 20174:06 pmRNSHolding(s) in Company
1st Feb 201712:07 pmRNSTotal Voting Rights
9th Jan 20179:00 amRNSAcquisition of FluxData
3rd Jan 20174:02 pmRNSTotal Voting Rights
1st Dec 201611:37 amRNSTotal Voting Rights
28th Nov 20163:05 pmRNSDirector/PDMR Shareholding
24th Nov 20164:18 pmRNSDirector/PDMR Shareholding
22nd Nov 20164:35 pmRNSDoc re. Half Yearly Report
22nd Nov 20167:00 amRNSHalf-year Report
1st Nov 20164:43 pmRNSTotal Voting Rights
5th Oct 20165:51 pmRNSDirector/PDMR Shareholding
3rd Oct 20164:31 pmRNSTotal Voting Rights
29th Sep 201610:00 amRNSInvestor Event
27th Sep 20169:37 amRNSDirectorate Change
23rd Sep 20164:27 pmRNSDirectorate Change
1st Sep 20165:25 pmRNSTotal Voting Rights
22nd Aug 20163:54 pmRNSDirector/PDMR Shareholding
10th Aug 20163:26 pmRNSDirector/PDMR Shareholding
1st Aug 20169:00 amRNSTotal Voting Rights
28th Jul 20163:06 pmRNSDirector/PDMR Shareholding
21st Jul 20166:01 pmRNSResult of AGM
21st Jul 20167:00 amRNSAGM Trading Update
1st Jul 201612:58 pmRNSTotal Voting Rights
21st Jun 20162:38 pmRNSAnnual Financial Report
14th Jun 20167:00 amRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.